Table 1: Patients’ baseline characteristics and reason for switch of intravitreal therapy.

Anti-VEGF to dexamethasone Dexamethasone to anti-VEGF Dexamethasone

BRVO73% (22)67% (4)45% (5)
CRVO20% (6)17% (1)55% (6)
Gender (% female)50%50%45%
Age (at baseline [years])69 ± 1070 ± 1374 ± 12
BCVA before switch (mean ± SD [logMAR])0.42 ± 0.280.55 ± 0.341.07 ± 0.69
BCVA before switch (mean ± SD [logMAR])0.36 ± 0.310.52 ± 0.450.88 ± 0.50
Number of intravitreal injections before switch (median, quartiles)6 [3.25; 10]1.5 [1;2]
Reason for switch
(i) Deterioration40% (12)33% (2)
(ii) Stagnation47% (14)67% (4)
(iii) Patients’ choice3% (1)0
(iv) IOP decompensation3% (1)0
(v) Not known7% (2)0

BRVO/CRVO: branch/central retinal vein occlusion; BCVA: best-corrected visual acuity.